Comparative study of adefovir dipivoxil combined with lamivudine and adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B patients with lamivudine resistance

Objective To evaluate the effect of adefovir dipivoxil combined with lamivudine treatment and adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B patients with lamivudine resistance. Methods Sixty chronic hepatitis B patients with lamivudine resistant were divided into the combination and monotherapy group. The combination group applied adefovir dipivoxil 10 mg/d and lamivudine 100 mg/d for 96 weeks, while the monotherapy group applied adefovir dipivoxil 10 mg/d for 96 weeks. Results After treatment, the negative rate of HBV DNA, HBeAg, ALT were 93.3%, 53.3%, 83.3% in the combination group and 66.7%, 26.7%, 56.7% in the monotherapy group, with statistically significant difference between the two groups. No cases of resistance was found in the combination group, but 6 were found in the monotherapy group. Conclusion Adefovir dipivoxil combined with lamivudine was superior to adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B patients with lamivudine resistance.